查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1676714

BNP 和 NT-proBNP 市場按類型、測試類型、組件、技術、銷售管道、應用和最終用戶分類 - 2025-2030 年全球預測

Bnp & Ntprobnp Market by Type, Test Type, Component, Technology, Sales Channel, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年 BNP 和 NT-proBNP 市場價值預估為 19.6 億美元，預計 2025 年將達到 21.8 億美元，預計到 2030 年將以 11.30% 的複合年成長率成長至 37.3 億美元。

主要市場統計數據
基準年 2024 年 19.6億美元
預計 2025 年 21.8億美元
預測年份 2030 37.3億美元
複合年成長率（%） 11.30％

近年來，在科技的快速進步和醫療保健需求不斷變化的推動下，診斷市場經歷了重大轉變。本報告深入分析了影響檢測套組和 NT-proBNP檢測套組的動態情勢。該介紹強調了範式轉移和市場演變，為理解當前發揮作用的多方面力量奠定了基礎。

該分析基於當前的市場促進因素，例如技術創新、不斷變化的區域動態和策略性產業動向。它不僅摘要了臨床實驗室診斷的發展軌跡，還將新興趨勢與關鍵患者照護領域的實際應用聯繫起來。認知到產品開發、技術發展和監管條件的相互依賴性對於產業適應新的競爭挑戰至關重要。

本摘要探討了當前的市場狀況，評估了從臨床創新到採用新測試方法等關鍵因素。目的是提供對未來挑戰和機會的全面和細緻的見解，使決策者能夠利用報告的見解並做出明智的策略舉措。本報告中提出的見解是廣泛的市場研究和對產業格局的全面評估的結果。

診斷產業的變革

最近的趨勢正在推動診斷市場的重大變革，從根本上改變了整個醫療保健系統中檢測套組的開發、分發和使用方式。先進技術與資料主導方法的融合正在重塑市場動態，創造一個不僅歡迎創新而且期待創新的環境。

技術透過生物感測器、免疫測量和微流體的整合在重新定義市場策略方面發揮關鍵作用。這些技術創新不僅提高了檢測性能，而且還使實驗室和臨床點的操作更加簡化。從傳統實驗室方法逐漸轉向快速即時檢測，證明了市場的彈性和適應性。

同時，監管改革和更強力的品管措施的出現為診斷行業帶來了更大的透明度和可信度。競爭日益激烈的環境凸顯了這種轉變，人們越來越重視效率和準確性。企業被迫重新評估和調整其策略以保持市場相關性。這種轉變將科學進步和卓越的營運結合在一起，因此，將策略與這些變化相結合的公司將更有能力實現永續成長。

市場正在擁抱數位轉型，其生態系統支援即時資料分析、更快的周轉時間以及增強臨床醫生和實驗室專業人員之間的溝通。自動化、準確性和速度等業務流行語現已成為現代診斷的代名詞。在這種背景下，不斷變化的格局不僅意味著技術創新，還意味著重組經營模式以跟上醫療保健產業的快速發展。

多層面的市場區隔洞察

詳細的細分洞察可以更深入地了解檢測套組產業的多樣化市場組成部分。市場依產品類型進行清楚分析，BNP檢測套組和 NT-proBNP檢測套組分類明確。這種區別表明了策略定位機會，因為每種測試類型在臨床和照護現場環境中都具有獨特的優勢。

根據測試類型進一步細分，顯示兩個管道：實驗室測試和即時診斷測試。在實驗室測試中，人們非常關注化學冷光免疫檢測(CLIA) 和酵素結合免疫吸附檢測法(ELISA) 等技術，這些技術的效率和特異性不斷提高。此外，區分組件（例如分析儀器或與試劑和套件結合的儀器）的細分可以揭示額外的價值。在此領域中，分析儀器和設備進一步分為桌上型和可攜式，突顯了在各種醫療環境中對多功能性的需求。

技術領域包括採用生物感測器、免疫測量和微流體，這些技術處於技術創新的前沿。這些技術代表了精密工程與快速性能的結合，這對於當今快節奏的診斷工作至關重要。隨著傳統分銷網路擴展到數位管道，銷售管道分為線下和線上反映了消費者行為的演變。基於應用的細分涵蓋了心臟衰竭管理、腎功能障礙、風險評估等關鍵領域，同時也增加了新的方面。心臟衰竭管理包括對急性心臟衰竭的詳細分析，其中急性心臟衰竭又包括心源性休克和補償心臟衰竭等子區隔。即使在右心臟衰竭領域，諸如肺冠狀動脈症候群等疾病也被確定為需要更深入臨床洞察的獨立領域。

細分涵蓋最終用戶的分析，從臨床實驗室到醫院和診所，甚至研究和學術機構。在臨床實驗室類別中，診斷實驗室和研究實驗室之間的差異提供了清晰的見解。例如，診斷實驗室又分為生物化學檢驗實驗室和病理實驗室。每一層細分不僅凸顯了診斷市場的固有複雜性，也凸顯了設計目標策略時必須考慮的細微差別。整合這些多層次的見解將有助於相關人員制定更準確的市場方法，並利用有望實現更高成長和創新的子區隔。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 提高人們對早期診斷和監測心臟相關疾病益處的認知
      • 全球心血管疾病和心臟衰竭盛行率不斷上升
      • 支持政府針對預防和管理心臟病的政策和舉措
    • 限制因素
      • 缺乏標準化導致分析結果不一致
    • 機會
      • 創新照護現場利鈉肽檢測，提高可及性和採用率
      • 擴大 NTproBNP 在個人化和精準醫療策略中的應用
    • 任務
      • 由於腎功能和肥胖等因素，生物標記水平的解釋存在挑戰
  • 市場區隔分析
    • 測試類型：實驗室測試由於其高敏感性和特異性而越來越受到青睞。
    • 最終用戶：既定的通訊協定正在推動臨床實驗室中 BNP 和 NT-proBNP 的使用增加。
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會的
    • 技術的
    • 合法的
    • 環境

6. BNP 和 NT-proBNP 市場按類型分類

  • BNP 檢測試劑套件
  • Ntprobnp 測試套件

7. BNP 和 NT-proBNP 市場（按測試類型）

  • 實驗室測試
    • 化學冷光免疫檢測(CLIA)
    • 酵素免疫分析法（ELISA）
  • 就地檢驗

8. BNP 和 NT-PROBNP 市場按成分分類

  • 分析儀器及設備
    • 桌上型分析儀
    • 可攜式分析儀
  • 試劑和套件

9. BNP 和 NT-PROBNP 市場依技術分類

  • 生物感測器
  • 免疫檢測
  • 微流體

10. BNP 和 NT-PROBNP 市場按銷售管道

  • 線下銷售
  • 網上銷售

第 11 章 BNP 和 NT-proBNP 市場（按應用）

  • 心臟衰竭管理
    • 急性心臟衰竭
      • 心源性休克
      • 補償心臟衰竭
    • 慢性心臟衰竭衰竭
      • 雙心室心臟心臟衰竭
      • 左心臟衰竭
      • 右心臟衰竭
      • 肺心
  • 腎功能障礙
    • 急性腎損傷
    • 慢性腎臟病
  • 風險評估
    • 預後評估
      • 死亡風險評估
      • 再入院風險評估
    • 心血管疾病篩檢

12. BNP 和 NT-PROBNP 市場按最終用戶分類

  • 臨床實驗室
    • 診斷實驗室
      • 生物化學實驗室
      • 病理實驗室
    • 研究部門
  • 醫院和診所
  • 研究和學術機構

13. 美洲 BNP 和 NT-proBNP 市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

14. 亞太地區 BNP 和 NT-proBNP 市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

15. 歐洲、中東和非洲 BNP 和 NT-proBNP 市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • Abbott Laboratories
  • Autobio Diagnostics Co., Ltd.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc
  • bioMerieux PLC
  • Chengdu Illumaxbio Technology Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Fujirebio China Co., Ltd.
  • Gentian Diagnostics ASA
  • Getein Biotech, Inc.
  • QuidelOrtho Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Europe NV
Product Code: MRR-4F7A6D4FEFB1

The Bnp & Ntprobnp Market was valued at USD 1.96 billion in 2024 and is projected to grow to USD 2.18 billion in 2025, with a CAGR of 11.30%, reaching USD 3.73 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.96 billion
Estimated Year [2025] USD 2.18 billion
Forecast Year [2030] USD 3.73 billion
CAGR (%) 11.30%

The diagnostics market has undergone a profound transformation in recent years, driven by rapid advancements in technology and changing healthcare demands. In this report, insights are provided into the dynamic landscape influencing Bnp Test Kits and Ntprobnp Test Kits. With an emphasis on shifting paradigms and market evolution, the introduction lays the foundation for understanding the multi-faceted forces at play.

This analysis is built upon current market drivers including technological innovation, evolving regional dynamics, and strategic industry moves. The narrative not only encapsulates the trajectory of laboratory diagnostics but also connects the emerging trends with real-world applications in critical patient care sectors. As the industry adapts to new competitive challenges, it is imperative to recognize the interdependencies between product development, technological evolutions, and regulatory conditions.

In exploring the current state of the market, this summary evaluates key components from clinical innovation to the adoption of novel testing methodologies. The goal is to provide a comprehensive, nuanced look into both the challenges and the opportunities that lie ahead, ensuring that decision-makers can leverage the report's insights to make informed strategic moves. The insights presented herein are the culmination of extensive market research and an in-depth evaluation of the industry's operational landscape.

The Evolutionary Shifts Reshaping the Diagnostics Landscape

Recent years have signified transformative shifts in the diagnostics market, fundamentally altering the way test kits are developed, marketed, and utilized across healthcare systems. The convergence of advanced technologies with a data-driven approach is reshaping market dynamics and fostering an environment where innovation is not only welcomed but expected.

Technology has played a pivotal role in redefining market strategies through the integration of biosensors, immunoassays, and microfluidics. These innovations have not only enhanced test performance but have also led to more streamlined operations in both laboratory-based and point-of-care settings. The gradual shift from traditional laboratory methods toward rapid, point-of-care testing is a testament to the market's resilience and adaptability.

Concurrently, the emergence of regulatory reforms and more robust quality control measures has increased transparency and trust in the diagnostics sector. The transformation is underscored by the rising emphasis on both efficiency and accuracy, factors that have led to a more competitive environment. Organizations are compelled to revisit and recalibrate their strategies to maintain market relevance. This shift integrates scientific progress with operational excellence; hence, companies that align their strategies with these changes are better positioned for sustainable growth.

The market has embraced digital transformation with an ecosystem that supports real-time data analysis, quicker turnaround times, and enhanced communication between clinical practitioners and laboratory specialists. Operational buzzwords such as automation, precision, and speed have now become synonymous with modern diagnostics. In this context, the evolving landscape is not just about technological innovation but also about reimagining business models to meet the fast-evolving demands of the healthcare sector.

Elucidating Market Segmentation Insights Across Multiple Dimensions

Detailed segmentation insights unlock a deeper understanding of the diverse market components in the test kit industry. The market is distinctly analyzed by product type with a clear demarcation between Bnp Test Kits and Ntprobnp Test Kits, each tailored to address specific clinical needs. This distinction signals an opportunity for strategic positioning as each test type offers unique advantages in clinical and point-of-care settings.

Further segmentation based on test type illustrates the dual channels of laboratory testing and point-of-care testing. Within laboratory testing, significant attention is directed towards techniques such as Chemiluminescent Immunoassay (CLIA) and Enzyme-linked Immunosorbent Assay (ELISA), which continue to evolve in efficiency and specificity. Additionally, the segmentation that distinguishes components, including analyzers and devices paired with reagents and kits, reveals another layer of value. In this segment, analyzers and devices are further classified into benchtop analyzers and portable analyzers, underscoring the need for versatility in various healthcare settings.

Technological segmentation encompasses the adoption of biosensors, immunoassays, and microfluidics that are at the forefront of innovation. These technologies illustrate the melding of precision engineering with rapid performance, which is crucial in today's fast-paced diagnostic landscape. The sales channel segmentation between offline and online sales channels further showcases the evolving consumer behavior as traditional distribution networks expand to incorporate digital channels. The application-based segmentation adds yet another dimension, covering key areas such as heart failure management, kidney dysfunction, and risk assessment. In heart failure management, both acute and chronic forms are closely analyzed with additional sub-segments including cardiogenic shock and decompensated heart failure in the acute category, while chronic heart failure is further dissected into biventricular, left-sided, and right-sided manifestations. Even within the right-sided heart failure segment, conditions such as cor pulmonale are identified as distinct areas requiring deeper clinical insight.

The segmentation extends to analysis by end user, ranging from clinical laboratories to hospitals and clinics, and further to research institutes and academia. Within the clinical laboratories category, distinct insights are revealed by differentiating between diagnostic and research laboratories; for instance, diagnostic laboratories are further divided into biochemistry labs and pathology labs. Each segmentation layer not only highlights the complexity inherent in the diagnostics market but also underscores the nuances that must be considered when designing targeted strategies. Integrating these multi-level insights allows industry stakeholders to develop more precise market approaches and capitalize on sub-segments that promise higher growth and innovation.

Based on Type, market is studied across Bnp Test Kits and Ntprobnp Test Kits.

Based on Test Type, market is studied across Laboratory Testing and Point-of-Care Testing. The Laboratory Testing is further studied across Chemiluminescent Immunoassay (CLIA) and Enzyme-linked Immunosorbent Assay (ELISA).

Based on Component, market is studied across Analyzers & Devices and Reagents & Kits. The Analyzers & Devices is further studied across Benchtop Analyzers and Portable Analyzers.

Based on Technology, market is studied across Biosensors, Immunoassays, and Microfluidics.

Based on Sales Channel, market is studied across Offline Sales and Online Sales.

Based on Application, market is studied across Heart Failure Management, Kidney Dysfunction, and Risk Assessment. The Heart Failure Management is further studied across Acute Heart Failure and Chronic Heart Failure. The Acute Heart Failure is further studied across Cardiogenic Shock and Decompensated Heart Failure. The Chronic Heart Failure is further studied across Biventricular Heart Failure, Left-Sided Heart Failure, and Right-Sided Heart Failure. The Right-Sided Heart Failure is further studied across Cor Pulmonale. The Kidney Dysfunction is further studied across Acute Kidney Injury and Chronic Kidney Disease. The Risk Assessment is further studied across Prognostic Evaluation and Screening for Cardiovascular Diseases. The Prognostic Evaluation is further studied across Mortality Risk Assessment and Readmission Risk Assessment.

Based on End User, market is studied across Clinical Laboratories, Hospitals & Clinics, and Research Institutes & Academia. The Clinical Laboratories is further studied across Diagnostic Laboratories and Research Laboratories. The Diagnostic Laboratories is further studied across Biochemistry Labs and Pathology Labs.

A Comprehensive Analysis of Global Market Regions

Expanding the geographical lens, the market exhibits significant regional diversity, with critical insights emerging from key regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, well-established healthcare systems and advanced diagnostic infrastructures set the stage for market expansion, providing a canvas where innovation and policy converge to stimulate growth. The robust regulatory framework and heightened public-private collaborations act as catalysts for rapid market deployment in these territories.

The region commonly referred to as Europe, Middle East & Africa presents a mix of mature markets coupled with burgeoning opportunities in developing economies. Regulatory harmonization in European nations, coupled with rising investments in healthcare infrastructure in parts of Africa and the Middle East, creates fertile ground for advancing diagnostics technologies. This regional perspective is enriched by the diverse economic profiles and healthcare challenges across these territories, offering a unique environment that balances established practices with transformative potential.

In contrast, the Asia-Pacific region represents a fast-evolving market characterized by rapid industrialization and expanding healthcare needs. With an accelerating pace of technological adoption and an increasing volume of clinical data, the Asia-Pacific not only acts as a hotbed for innovation but also as a key driver for market growth globally. Here, local innovators and multinational corporations are continuously adapting to a dynamic environment that values speed, adaptability, and efficiency. The backdrop of diverse health challenges coupled with significant population density propels an urgent need for advanced testing solutions across this region.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Prominent Industry Leaders Painting the Competitive Canvas

The competitive landscape of the diagnostics market is marked by the robust presence of several high-caliber companies. Companies such as Abbott Laboratories, Autobio Diagnostics Co., Ltd., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., and bioMerieux PLC exemplify industry leadership through their consistent commitment to innovation and quality. These firms are complemented by dynamic players including Chengdu Illumaxbio Technology Co., Ltd., F. Hoffmann-La Roche Ltd, and Fujirebio China Co., Ltd., which have also significantly influenced the market trajectory.

Gentian Diagnostics ASA and Getein Biotech, Inc. further enrich the competitive tableau with tailored solutions that address specific clinical needs, while QuidelOrtho Corporation, Radiometer Medical ApS, and Randox Laboratories Ltd. have demonstrated robust distribution capabilities and market penetration strategies. In addition, industry titans such as Siemens AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Tosoh Europe N.V. contribute to the sector's landscape by continuously pushing the envelope in research and development. The collective insights from these industry leaders not only highlight the scale and sophistication of the marketplace but also underscore the strategic synergy between innovation and execution that defines the competitive space. Their ongoing investments in technological advancements and market expansion echo a common theme-a steadfast commitment to improving diagnostic accuracy and delivering patient-centric solutions across global markets.

The report delves into recent significant developments in the Bnp & Ntprobnp Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Autobio Diagnostics Co., Ltd., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc, bioMerieux PLC, Chengdu Illumaxbio Technology Co., Ltd., F. Hoffmann-La Roche Ltd, Fujirebio China Co., Ltd., Gentian Diagnostics ASA, Getein Biotech, Inc., QuidelOrtho Corporation, Radiometer Medical ApS, Randox Laboratories Ltd., Siemens AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Tosoh Europe N.V.. Actionable Strategies for Market Influence and Growth

Industry leaders are encouraged to leverage the insights detailed in this report to redefine and recalibrate their strategic objectives in the diagnostic arena. A multi-pronged strategy that integrates innovation with market-specific approaches is imperative for maintaining competitive momentum and ensuring sustainable growth. First and foremost, adopting an agile approach to technological innovations is essential. Embracing the latest research in biosensors, immunoassays, and microfluidics, while refining laboratory and point-of-care testing protocols, will drive advancements that resonate with modern clinical workflows.

Companies should also consider investing in tailored product development that aligns with the distinct sub-segments within the market. From the classification of test kits by type to the fine-grained distinctions in analytical methods and applications, there is significant potential in crafting solutions that cater to specific clinical needs. In parallel, optimizing distribution channels, whether by strengthening traditional offline networks or enhancing the digital landscape through online sales platforms, will be critical. Optimizing these channels not only broadens market access but also facilitates more direct engagement with healthcare providers and end users.

Further, businesses must dynamically respond to regional market trends. The diverse regulatory and economic environments in the Americas, Europe, Middle East & Africa, and Asia-Pacific necessitate adaptable strategies that respect local nuances while maintaining global standards. Strategic partnerships and local collaborations can provide a competitive edge, offering valuable insights into regional consumer needs and regulatory landscapes.

Moreover, in aligning product strategies with evolving market demands, companies must invest in robust research and development programs. This investment should focus on enhancing the specificity, efficiency, and accuracy of their testing solutions, thereby increasing clinical utility and reinforcing brand loyalty. Consistent monitoring of competitive movements and feedback from key opinion leaders is also necessary to ensure that product pipelines remain aligned with market expectations.

Finally, a comprehensive market communication strategy that emphasizes both transparency and educational value will enhance stakeholder engagement. By leveraging data-driven narratives that underscore the clinical and economic benefits of their offerings, companies can not only build trust but also elevate their market standing. In sum, actionable recommendations center around agility in innovation, market-specific customization, and the sustained pursuit of operational excellence.

Concluding Insights and Forward-Looking Perspectives

In summary, the dynamic diagnostics landscape is characterized by rapid technological innovations, evolving regulatory frameworks, and a complex segmentation structure that demands continuous re-evaluation. The interplay between laboratory testing and point-of-care methodologies consistently drives market advancements, while technological progress in areas such as biosensors, immunoassays, and microfluidics fuels permanent industry transformation.

The comprehensive segmentation analysis across product type, test methodologies, components, technology, sales channels, applications, and end users provides actionable insights that can effectively drive future market strategies. Furthermore, the detailed regional analysis of key market territories - encompassing the Americas, Europe, Middle East & Africa, and Asia-Pacific - highlights distinct market dynamics and opportunities for tailored growth strategies.

Additionally, the competitive landscape underpinned by innovative leaders such as Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories, and other industry giants reinforces the notion that continuous investment in research and development is crucial. The synthesis of these insights fosters a deep understanding of both current challenges and future opportunities. As the market evolves, stakeholders are positioned to capitalize on emerging trends and drive innovation in an increasingly competitive environment.

With robust strategies, agile adaptation, and a forward-looking approach that harmonizes technological innovation with market-specific demands, industry participants can usher in the next phase of growth. This concluding analysis underscores the importance of an integrated strategy that not only addresses the imperatives of today but also positions stakeholders for the opportunities of tomorrow.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness about the benefits of early diagnosis and monitoring for heart-related ailments
      • 5.1.1.2. Growing prevalence of cardiovascular diseases and heart failure worldwide
      • 5.1.1.3. Supporting government policies and initiatives focusing on heart disease prevention and management
    • 5.1.2. Restraints
      • 5.1.2.1. Variability in assay results due to lack of standardization
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in point-of-care natriuretic peptide tests to improve accessibility and adoption rates
      • 5.1.3.2. Expanding the use of NTproBNP in personalized medicine and precision health strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Challenges in interpreting biomarker levels due to factors such as renal function or obesity
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test Type: Rising preference for laboratory testing due to its high sensitivity and specificity
    • 5.2.2. End User: Rising use of BNP and NT-proBNP in clinical laboratories due to their established protocols
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bnp & Ntprobnp Market, by Type

  • 6.1. Introduction
  • 6.2. Bnp Test Kits
  • 6.3. Ntprobnp Test Kits

7. Bnp & Ntprobnp Market, by Test Type

  • 7.1. Introduction
  • 7.2. Laboratory Testing
    • 7.2.1. Chemiluminescent Immunoassay (CLIA)
    • 7.2.2. Enzyme-linked Immunosorbent Assay (ELISA)
  • 7.3. Point-of-Care Testing

8. Bnp & Ntprobnp Market, by Component

  • 8.1. Introduction
  • 8.2. Analyzers & Devices
    • 8.2.1. Benchtop Analyzers
    • 8.2.2. Portable Analyzers
  • 8.3. Reagents & Kits

9. Bnp & Ntprobnp Market, by Technology

  • 9.1. Introduction
  • 9.2. Biosensors
  • 9.3. Immunoassays
  • 9.4. Microfluidics

10. Bnp & Ntprobnp Market, by Sales Channel

  • 10.1. Introduction
  • 10.2. Offline Sales
  • 10.3. Online Sales

11. Bnp & Ntprobnp Market, by Application

  • 11.1. Introduction
  • 11.2. Heart Failure Management
    • 11.2.1. Acute Heart Failure
      • 11.2.1.1. Cardiogenic Shock
      • 11.2.1.2. Decompensated Heart Failure
    • 11.2.2. Chronic Heart Failure
      • 11.2.2.1. Biventricular Heart Failure
      • 11.2.2.2. Left-Sided Heart Failure
      • 11.2.2.3. Right-Sided Heart Failure
      • 11.2.2.3.1. Cor Pulmonale
  • 11.3. Kidney Dysfunction
    • 11.3.1. Acute Kidney Injury
    • 11.3.2. Chronic Kidney Disease
  • 11.4. Risk Assessment
    • 11.4.1. Prognostic Evaluation
      • 11.4.1.1. Mortality Risk Assessment
      • 11.4.1.2. Readmission Risk Assessment
    • 11.4.2. Screening for Cardiovascular Diseases

12. Bnp & Ntprobnp Market, by End User

  • 12.1. Introduction
  • 12.2. Clinical Laboratories
    • 12.2.1. Diagnostic Laboratories
      • 12.2.1.1. Biochemistry Labs
      • 12.2.1.2. Pathology Labs
    • 12.2.2. Research Laboratories
  • 12.3. Hospitals & Clinics
  • 12.4. Research Institutes & Academia

13. Americas Bnp & Ntprobnp Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Bnp & Ntprobnp Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Bnp & Ntprobnp Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Siemens Healthineers transforms heart failure diagnosis with innovative NT-proBNPII assay integration
    • 16.3.2. Roche Diagnostics pioneers NT-proBNP test for early CVD detection in diabetes patients via point-of-care systems
    • 16.3.3. Innovative hs-cTnI and NT-proBNP assays by Mindray enhance cardiac diagnostics precision and patient care
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Autobio Diagnostics Co., Ltd.
  • 3. Beckman Coulter, Inc.
  • 4. Bio-Rad Laboratories, Inc
  • 5. bioMerieux PLC
  • 6. Chengdu Illumaxbio Technology Co., Ltd.
  • 7. F. Hoffmann-La Roche Ltd
  • 8. Fujirebio China Co., Ltd.
  • 9. Gentian Diagnostics ASA
  • 10. Getein Biotech, Inc.
  • 11. QuidelOrtho Corporation
  • 12. Radiometer Medical ApS
  • 13. Randox Laboratories Ltd.
  • 14. Siemens AG
  • 15. Sysmex Corporation
  • 16. Thermo Fisher Scientific Inc.
  • 17. Tosoh Europe N.V.

LIST OF FIGURES

  • FIGURE 1. BNP & NTPROBNP MARKET MULTI-CURRENCY
  • FIGURE 2. BNP & NTPROBNP MARKET MULTI-LANGUAGE
  • FIGURE 3. BNP & NTPROBNP MARKET RESEARCH PROCESS
  • FIGURE 4. BNP & NTPROBNP MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL BNP & NTPROBNP MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BNP & NTPROBNP MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL BNP & NTPROBNP MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL BNP & NTPROBNP MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 25. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. BNP & NTPROBNP MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 31. BNP & NTPROBNP MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BNP & NTPROBNP MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BNP & NTPROBNP MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BNP & NTPROBNP MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BNP & NTPROBNP MARKET DYNAMICS
  • TABLE 7. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BNP TEST KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BNP & NTPROBNP MARKET SIZE, BY NTPROBNP TEST KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY (CLIA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BNP & NTPROBNP MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BNP & NTPROBNP MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BNP & NTPROBNP MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BNP & NTPROBNP MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BNP & NTPROBNP MARKET SIZE, BY OFFLINE SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CARDIOGENIC SHOCK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BNP & NTPROBNP MARKET SIZE, BY DECOMPENSATED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BIVENTRICULAR HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BNP & NTPROBNP MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COR PULMONALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BNP & NTPROBNP MARKET SIZE, BY MORTALITY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BNP & NTPROBNP MARKET SIZE, BY READMISSION RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SCREENING FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BIOCHEMISTRY LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PATHOLOGY LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL BNP & NTPROBNP MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 93. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 94. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 95. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 96. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 97. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 98. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 100. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. BRAZIL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. BRAZIL BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 110. BRAZIL BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 111. BRAZIL BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 112. BRAZIL BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 113. BRAZIL BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 114. BRAZIL BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 115. BRAZIL BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 116. BRAZIL BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. BRAZIL BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 118. BRAZIL BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. CANADA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 122. CANADA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 123. CANADA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 124. CANADA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. CANADA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. CANADA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. CANADA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 128. CANADA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 129. CANADA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 130. CANADA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 131. CANADA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 132. CANADA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 133. CANADA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 134. CANADA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. CANADA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 136. CANADA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 137. MEXICO BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. MEXICO BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. MEXICO BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 140. MEXICO BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 141. MEXICO BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 142. MEXICO BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. MEXICO BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. MEXICO BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. MEXICO BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 146. MEXICO BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 147. MEXICO BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 148. MEXICO BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 149. MEXICO BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 150. MEXICO BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 151. MEXICO BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 152. MEXICO BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. MEXICO BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 154. MEXICO BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 158. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 159. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 160. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 164. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 165. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 166. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 167. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 168. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 169. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 170. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 172. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 173. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 193. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 196. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 197. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 198. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 202. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 204. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 206. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 208. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 210. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 211. CHINA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. CHINA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. CHINA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 214. CHINA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 215. CHINA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 216. CHINA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. CHINA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. CHINA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. CHINA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 220. CHINA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 221. CHINA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 222. CHINA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 223. CHINA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 224. CHINA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 225. CHINA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 226. CHINA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. CHINA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 228. CHINA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 229. INDIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. INDIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. INDIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 232. INDIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 233. INDIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 234. INDIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. INDIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. INDIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. INDIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 238. INDIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 239. INDIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 240. INDIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 241. INDIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 242. INDIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 243. INDIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 244. INDIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. INDIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 246. INDIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 247. INDONESIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. INDONESIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. INDONESIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 250. INDONESIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 251. INDONESIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 252. INDONESIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. INDONESIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. INDONESIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. INDONESIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 256. INDONESIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 257. INDONESIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 258. INDONESIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 259. INDONESIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 260. INDONESIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 261. INDONESIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 262. INDONESIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. INDONESIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 264. INDONESIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 265. JAPAN BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. JAPAN BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. JAPAN BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 268. JAPAN BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 269. JAPAN BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 270. JAPAN BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 271. JAPAN BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. JAPAN BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. JAPAN BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 274. JAPAN BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 275. JAPAN BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 276. JAPAN BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 277. JAPAN BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 278. JAPAN BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 279. JAPAN BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 280. JAPAN BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. JAPAN BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 282. JAPAN BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 283. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 286. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 287. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 288. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 289. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 290. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 291. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 292. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 293. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 294. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 295. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 296. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 297. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 298. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 299. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 300. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 301. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 304. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 305. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 306. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 307. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 308. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 309. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 310. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 311. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 312. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 313. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 314. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 315. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 316. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 317. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 318. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 319. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 322. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 323. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 324. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 325. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 326. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 328. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 329. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 330. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 331. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 332. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
  • TABLE 333. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
  • TABLE 334. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 335. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 336. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 337. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 340. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 341. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
  • TABLE 342. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 343. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 344. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 345. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 346. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 347. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 348. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 349. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
  • TABLE 350. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY RISK ASSE